Call for Abstracts Submission
Abstract Submissions Open Wednesday 10 April 2024
Whether you are a student, early career, mid or senior researcher, you are warmly invited to submit an abstract for consideration. You are encouraged to share your learnings, insights and stories to address the conference theme ‘Advancing research and patience care’.Call for Abstracts Key Dates
| Abstract Submissions Open | Wednesday 10 April 2024 |
| Abstract Submissions Close | Thursday 1 August 2024 |
| Outcome Notification | Friday 13 September 2024 |
| Presenters are required to register for Luminesce Alliance Conference 2024 | Friday 4 October 2024 |
Presentation Types
You are invited to submit using one of three presentation formats:-
- Concurrent Oral Presentation Session: oral presentation (10 minutes plus 5-minute question time)
- Rapid Fire Oral Presentation: brief oral presentation (5 minutes)
- Poster Presentation: hard copy posters will be on display with authors in attendance at a specified day/time to discuss their research with interested delegates.
Please note:
- Spaces for oral presentations are limited and abstracts not selected for oral presentations may be offered a poster presentation.
- Speaker guidelines will be provided closer to the date.
- Abstracts from students and Early Career Researchers (ECRs) are strongly encouraged.
Submission Guidelines
Introduction
- All Submissions must comply with these guidelines
- The Scientific Committee reserves the right to reject or return for re-submission with a strict deadline any abstract that does not comply with these guidelines.
- For each abstract, select ONE of the listed Topics and ONE Category of basic science, translational, or clinical research.
- Based on these selections the committee will assign reviewers with corresponding expertise to rate your abstract.
Step 1 – Topic – Select one only
- Functional Genomics
- Advanced Genome and Transcriptome Analytics
- Advanced Clinical Data Analytics
- Data Integration
- Drug screening and pre-clinical testing
- Advanced therapeutics, therapy, novel target and agents, clinical trials
- Psychosocial
- Health Economics
- Health Systems Implementation
Step 2 – Category – Select one only
- Basic Science
- Translational
- Clinical
Abstract Content
Abstracts should comprise the following elements entered into the submission portal in the corresponding sections.
1. Title
- A brief descriptive title (maximum of 12 words) in Sentence Trademarks are not permitted.
2. Authors and Affiliations
- Institutional affiliations should include the city, state, and country. Each affiliation should be input in a separate section and will be allocated a superscript number.
- Authors’ names and details should be entered as instructed in the portal.
- You must also indicate who will be the presenting author.
3. Abstract
- There is a maximum of 300 words allowed only (do not include tables, charts, and pictures). The abstract text must not exceed 300 words, excluding the abstract title and author details.
- Text must be submitted as plain text without formatting. A limited number of symbols are available from the Special Character Keyboard.
- Tables, graphs, and charts are NOT permitted in abstracts.
- Abstracts should be carefully proofread and free of typographical and grammatical errors. The Scientific Committee reserves the right to correct abstracts for obvious spelling or grammatical errors without notice.
- Standard abbreviations may be used for common terms only. Otherwise, any abbreviation should be given in brackets after the first full use of the word.
- Abbreviations may be used in the title, provided the name in full is outlined in the body of the abstract.
Abstract sections
Abstracts should contain the following sections, each beginning a new paragraph:
- Background: Aims and objectives of the study, what the study covers, relevant background information, and an outline of how the information will be
- Methods: Outline how the study was carried out and how the information was
- Results: Present the results obtained from data gathering and the study. Results should be presented clearly, and concisely and record only the facts.
- Conclusion: State or summarise the main points or findings of the This is where the aims of the study are revisited. No new information should be presented in this section.
Session Recording
Please note that by submitting your abstract and or agreeing to present, that you are consenting to your presentation being recorded for upload to www.luminesceallianceconference.org.au post the conference. If you do not wish your session to be recorded you can tick the opt out option during the submission process.
Terms and Conditions
- All abstracts must be original work and must be related to paediatric research and one of the major topics listed under “Abstract topic”.
- Abstracts must be submitted by the first or corresponding author and only 2 abstracts per first author can be submitted.
- An abstract must contain sufficient information so that, if published, it will be a complete report independent of presentation.
- The text should not contain statements alluding to results or conclusions not presented within the text.
- Abstracts pertaining to commercial promotion of a proprietary product will not be accepted.
- The Scientific Committee has the right of refusal to any abstract submitted at all
- All presenting authors (maximum of two) if selected by the Scientific Committee must register and pay to attend the Conference by Friday 4 October 2024. Alternate presenters need to be approved by the Scientific Committee.
Abstract Review
All submitted abstracts will be reviewed by at least two reviewers. In evaluating each abstract, reviewers will be unaware of authors or institutions involved with the work described in the abstract. The following criteria will be used when assessing the abstract:
- Does the abstract address a relevant area related to paediatric research and the major topics listed? Is the methodology adequate and acceptable? Have the data/findings been interpreted appropriately? Are the results clearly presented? Are the conclusions supported by the presented data? Are the contents of the abstract clear and intelligible?
Abstracts on completed studies and research outcomes may be given preference in selecting the oral presentations, over abstracts that do not report results but indicate that they will be reported at the meeting or contain descriptions of trial methodology.
Notification of Outcome
Notification of outcome/acceptance will be emailed to the submitting author by Friday 13 September 2024.It is the submitting author’s responsibility to notify all other authors about the outcome of the reviewers’ decision.
Oral Presentation and Poster Display
From the accepted abstracts a selection will be scheduled for the concurrent oral presentation session and the rapid-fire oral presentation and poster display only.
For all accepted abstracts, further details regarding the oral presentation (PowerPoint presentation) and poster presentation (poster size, format, style and layout etc.) will be communicated to the submitting author.
Presenting Author Registration
If the presenting author cannot present at the time/date for the scheduled concurrent oral presentation session and the rapid-fire oral presentation an alternate can be considered. Alternate presenters need to be approved by the Scientific Committee.
No-Show Policy
Should a presenting author be absent without notice during the oral presentation sessions where the abstract is scheduled to be presented, the presentation will be cancelled.
Trademarks
Trademarks may be used in the abstract text but only in brackets and only once, i.e. the first time the product/service is mentioned. The identity of drugs/technologies described in the abstract should be disclosed using a generic name, a brief description or a reference to a public source.
Abstract Publication / Copyright
Submission of an abstract grants Luminesce Alliance permission to publish the abstract in the Luminesce Alliance 2024 Conference Online Program as well as the Luminesce Alliance websites www.luminesceallianceconference.org.au and www.luminesce.org.au. Links to the online program will be made from the Luminesce Alliance monthly newsletter, social media posts and industry publications (such as OHMR and Research Australia).
It is expected that the primary author/presenter will consult with co-authors/supervisors to provide consent for the abstract to be published. Abstract authors retain full copyright.
Contact
For questions or assistance with abstract submission please contact lac2024@expertevents.com.au
Frequently Asked Questions and Key Dates
Key Dates
| Abstract Submissions Open | Wednesday 10 April 2024 |
| Abstract Submissions Close | Thursday 1 August 2024 |
| Outcome Notification | Friday 13 September 2024 |
| Presenters are required to register for Luminesce Alliance Conference 2024 | Friday 4 October 2024 |
What is an abstract?
An abstract is a concise, standalone statement briefly summarising the essential information of a study, encompassing its purpose, methods, results, and conclusions. A well-crafted abstract serves to showcase your project, contribute to practice or education, and foster connections with fellow researchers.
How many abstracts can I submit?
Each first author may submit up to two abstracts, but the same research cannot be submitted twice, even under a different topic/category or with a different title.
Can I submit an abstract by email?
No. Abstracts can be submitted only via the online abstract submission portal. Any abstract sent by email will not be accepted and automatically returned to the sender.
Who can submit an abstract?
Abstracts will only be accepted from the first author or a designated corresponding author of the submitted abstract who has registered and agrees to attend, upon selection, the Luminesce Alliance 2024 Conference. If you fail to register to attend the conference, the selected abstract will be withdrawn.
Who reviews the abstracts?
Submitted abstracts will be blind-reviewed and selected by the Scientific Review Committee.
How will your abstract be assessed?
The following criteria will be used when assessing the abstract: Does the abstract address a relevant area related to paediatric research and the major topics listed? Is the methodology adequate and acceptable? Have the data/findings been interpreted appropriately? Are the results clearly presented? Are the conclusions supported by the presented data? Are the contents of the abstract clear and intelligible?
The Scientific Review Committee will not accept abstracts about commercial promotion of a proprietary product.
How many words should my abstract contain?
There is a maximum of 300 words excluding tables and pictures. The 300-word limit excludes the title and authors.
Are there other general submission requirements?
Writing must be clear, concise, and grammatically correct. Abstracts and posters may not contain any type of advertising.
Can I submit an abstract that has been previously presented or published?
Only if there are considerable changes (e.g. new data). This needs to be validated by the author.
When will I hear whether my abstract was accepted or rejected?
Submitting authors will receive notification of the selection outcome via e-mail by Friday 13 September 2024.
Will all co-authors or third parties be notified?
No. Only the submitting author will be notified. It is up to the submitting author to notify the presenting author/co-authors.
If my abstract is accepted what happens?
You will receive notification regarding the acceptance of your abstract for one of the following presentation types at the Luminesce Alliance 2024 Conference:
- Concurrent Oral Presentation Session: oral presentation (10 minutes plus 5-minute question time)
- Rapid Fire Oral Presentation: 5-minute brief oral presentation
- Poster Presentation
If selected, you must register and pay for the conference to present your work either face-to-face at an assigned time for oral presentations or to discuss your research during specific day/time slots for hard copy posters. This also applies to corresponding authors wishing to attend the conference. The registration fee is non-refundable in case of non-attendance.
Are all the authors eligible for the reduced registration rate?
There is no special registration rate for abstract authors. However, students are offered a reduced registration rate.
Can I change the assigned Presenter?
The presenting author can be changed, please send an email to lac2024@expertevents.com.au with the abstract title/paper number, advising the change. The presenter must be part of the submitted authors’ list and be able to present and discuss all aspects of the research.
What if the assigned presenter cannot attend the oral presentations?
Should a presenting author be absent without notice during the oral presentation sessions where the abstract is scheduled to be presented, the presentation will be cancelled.
What do you mean by assigning and transferring rights and copyright to the Luminesce Alliance?
The content belongs to the author(s) but if the abstract is accepted, the submitter agrees on behalf of all co-authors to give Luminesce Alliance the right to reproduce and distribute the work submitted.
I need to withdraw my abstract. How should I proceed?
The submitting author needs to send an email to lac2024@expertevents.com.au with the abstract title/paper number, advising that they wish to withdraw.
Where and when will my abstract be published?
All accepted abstracts will be available on the Luminesce Alliance 2024 Conference website once the program launches.
Where do I find the information on the presentation format for my oral and poster?
Detailed information related to your abstract presentation will be provided by email as part of your advice on the results of the selection process.
Who is my audience?
Meeting delegates include scientists, clinicians, researchers, trainees, government, and other health representatives.
Can I change/edit my abstract?
Prior to the abstract submission deadline (Thursday 1 August 2024), you can edit your abstract directly in the abstract submission portal if it is saved as a draft. Any changes to a submitted abstract must to be emailed to lac2024@expertevents.com.au prior to the abstract submission deadline, as you cannot edit directly in the portal once the status is submitted.